Ohr Pharmaceuticals (NASDAQ:OHRP) was downgraded by research analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research report issued on Friday.
Several other research firms have also recently commented on OHRP. Zacks Investment Research upgraded shares of Ohr Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 price target for the company in a report on Wednesday, October 18th. Roth Capital cut shares of Ohr Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $7.00 price target for the company. in a report on Friday.
Ohr Pharmaceuticals (NASDAQ:OHRP) traded down $1.64 during mid-day trading on Friday, hitting $0.38. 34,330,000 shares of the company traded hands, compared to its average volume of 2,340,000. The firm has a market capitalization of $21.19, a PE ratio of -0.64 and a beta of 0.48. Ohr Pharmaceuticals has a twelve month low of $0.35 and a twelve month high of $2.18.
COPYRIGHT VIOLATION WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/05/ohr-pharmaceuticals-ohrp-stock-rating-lowered-by-valuengine.html.
About Ohr Pharmaceuticals
OHR Pharmaceutical, Inc, a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Ohr Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ohr Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.